Page last updated: 2024-08-05 11:01:19
retinoid
Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
ChEBI ID: 26537
Members (25)
| Member | Definition | Role |
|---|---|---|
| 13,14-dihydroretinoic acid | all-trans-13,14-dihydroretinoic acid | |
| 3-hydroxyretinal | all-trans-3-Hydroxyretinal | |
| 3-hydroxyretinol | all-trans-3-hydroxyretinol | |
| 3,4-didehydroretinoic acid | A retinoid obtained by 3,4-desaturation of beta-ionone ring of all-trans-retinoic acid | all-trans-3,4-didehydroretinoic acid |
| 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR). | arotinoid acid |
| 4-hydroxyretinal | A retinoid that is all-trans-retinal carrying a hydroxy substituent at position 4 on the cyclohexenyl ring. | all-trans-4-hydroxyretinal |
| 4-hydroxyretinoic acid | A retinoid that consists of all-trans-retinoic acid bearing a hydroxy substituent at position 4 on the cyclohexenyl ring. | all-trans-4-hydroxyretinoic acid |
| 4-oxoretinoic acid | A retinoid that consists of all-trans-retinoic acid bearing an oxo substituent at position 4 on the cyclohexenyl ring. | all-trans-4-oxoretinoic acid |
| 4-oxoretinol | A retinoid that is all-trans-retinol in which the hydrogens at position 4 have been replaced by an oxo group. | all-trans-4-oxoretinol |
| 9,13-retinoic acid | 9,13-cis-Retinoic acid | |
| acitretin | A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9. | acitretin |
| acitretin | all-trans-acitretin | |
| agn 190299 | A thiochromane that is acetylene in which the hydrogens are replaced by 5-carboxypyridin-2-yl and 4,4-dimethylthiochroman-6-yl groups. It is the active form of the prodrug tazarotene. | tazarotenic acid |
| bexarotene | bexarotene | |
| etretinate | etretinate | |
| fenretinide | A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids. | 4-hydroxyphenyl retinamide |
| mannosylretinylphosphate | Retinylphosphate mannose | |
| motretinide | motretinide | |
| N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide | N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide | |
| retinoic acid | A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). | retinoic acid |
| retinoyl beta-glucuronide | A retinoid that is retinoic acid in which the carboxy proton has been replaced by a beta-D-glucuronyl residue. | 1-O-all-trans-retinoyl-beta-glucuronic acid |
| sr 11302 | A retinoid that is all-trans-retinoic acid in which the methyl group at position 9 is replaced by a 4-methylphenyl group. It is an inhibitor of activator protein-1 which exhibits antitumour effects in vivo. | SR11302 |
| tamibarotene | A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine. | tamibarotene |
| tazarotene | The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. | tazarotene |
| vitamin a2 | A retinoid derived from 3,4-desaturation of the beta-ionone ring of all-trans-retinol. | all-trans-3,4-didehydroretinol |
Research
Studies (4,819)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1,108 (22.99) | 18.7374 |
| 1990's | 952 (19.76) | 18.2507 |
| 2000's | 1,235 (25.63) | 29.6817 |
| 2010's | 1,134 (23.53) | 24.3611 |
| 2020's | 390 (8.09) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 546 (9.95%) | 5.53% |
| Reviews | 578 (10.54%) | 6.00% |
| Case Studies | 1,305 (23.79%) | 4.05% |
| Observational | 12 (0.22%) | 0.25% |
| Other | 3,044 (55.50%) | 84.16% |